Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling

Bharath Kumar Gajjela, Ming-Ming Zhou

Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the unprecedented COVID-19 pandemic, which has infected over 178 million people worldwide. Even with new vaccines, global herd immunity will not be reached soon. New cases and viral variants are being reported at an alarming rate. Effective antiviral treatment is urgently needed. Patients with severe COVID-19 suffer from life-threatening respiratory failure due to acute respiratory distress syndrome in their lungs, a leading cause of COVID-19 mortality. This lung hyper-inflammation is induced by virus-caused massive tissue damage that is associated with uncontrolled cytokine release, known as a cytokine storm, through JAK/STAT signaling pathways. Here, we review the FDA-approved JAK inhibitors that are being clinically evaluated and repurposed for the treatment of patients with severe COVID-19 by calming SARS-CoV-2 infection.

Keywords: COVID-19; Coronavirus disease 2019; Drug discovery; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2

Introduction

Coronavirus disease-19 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has infected more than 178 million people and caused 3.9 million fatalities worldwide as of mid-June 2021. SARS-CoV-2 was first identified in the respiratory tract of patients with pneumonia in Wuhan, China in December 2019. The COVID-19 symptoms that typically appear 2–14 days after viral exposure include fever, cough, shortness of breath and pneumonia. COVID-19 can reportedly range from a mild to a severe condition, and the latter can lead to death. Age and health problems such as chronic pulmonary or cardiac disease are risk factors that determine the mortality rate.

Newly introduced vaccines against SARS-CoV-2, most notably those developed by Oxford-AstraZeneca, Pfizer-BioNTech, Sinopharm-Beijing, and Moderna, have been administrated under Emergency Use Authorization in several countries, and have been shown to be effective in preventing the rapid spread of viral infection. However, worldwide COVID-19 herd immunity will probably...
not be reached for several years because low-to-middle income countries, including many in Africa, have an extremely low vaccination rate (currently 0.3%) or are yet to begin mass vaccination campaigns. New cases and viral variants are still being reported at an alarming rate, no specific treatment for COVID-19 exists, and the available clinical options are limited. Therefore, the development of effective treatments is an urgent need, especially for the life-threatening severe cases.

SARS-CoV-2 is an enveloped virus that contains single-stranded positive-sense RNA (+ssRNA), with 5-cap structure and a 3-poly-A tail, and belongs to the Betacoronavirinae subfamily of the Coronaviridae family, which causes illness in birds, mammals and humans. The viral genome is 27–32 kb that encodes both structural and non-structural proteins. SARS-CoV-2 comprises four main structural proteins, the spike (S) glycoprotein, the small envelope (E) glycoprotein, the membrane (M) glycoprotein, and the nucleocapsid (N) protein, as well as several accessory proteins. The spike protein, which is key for viral entry and replication in infected host cells, is composed of two functional subunits. The S1 subunit binds to host cell receptors, whereas the S2 subunit mediates the fusion of the viral and host cellular membranes. The distal part of the S1 subunit contains the receptor binding domain (RBD) that directly binds to the peptidase domain of angiotensin converting enzyme 2 (ACE2) of the host cell.

Upon entry into a host cell, SARS-CoV-2 releases its genetic material into the cytoplasm. The viral RNA is translated into polyproteins PP1a and PP1ab, which are subsequently cleaved into functional proteins by viral proteases. Sub-genomic templates for mRNA synthesis and the translation of viral structural proteins are formed through discontinuous transcription. Viral genome replication is mediated by a complex consisting of an RNA-dependent RNA polymerase (RdRp), a helicase, exonuclease N, and other accessory proteins. The assembly of viral nucleocapsids from the packaged viral genome and viral structural proteins takes place at the endoplasmic reticulum – Golgi intermediate compartment. The infectious virions are released from the cell through exocytosis.

**Immune response and cytokine storm in COVID-19 patients**

Clinically, host cells in the lungs elicit a two-phased response to SARS-CoV-2 infection (Fig. 1). In an early incubation and non-severe stage, alveolar macrophages detect the virus and produce cytokines (such as interferons) and chemokines that activate antiviral gene expression and recruit innate response cells (such as leukocytes, monocytes, natural killer (NK) cells, and dendritic cells) and adaptive immune cells to eliminate the virus and prevent disease progression. When this effort fails, or a protective immune response is impaired, the virus propagates. The disease transitions to a severe stage in which innate inflammation is induced by virus-caused massive tissue damage that is associated with uncontrolled cytokine release, known as a cytokine storm, from inflammatory macrophages and granulocytes. This results in acute respiratory distress syndrome (ARDS) in the lungs. COVID-19 patients in intensive care units (ICU) have been found to have higher concentrations of cytokines in their plasma than non-ICU patients, linking cytokines to disease severity. These proinflammatory cytokines and chemokines include tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β), IL-6, IL-10, IL-17, granulocyte/macrophage colony stimulating factor (GM-CSF), interferon γ (IFN-γ), monocyte chemoattractant protein-1 (MCP-1), and macrophage inflammatory protein 1-α (MIP-1α). They trigger immune cells to release a large number of free radicals that can cause pneumonia and ARDS, cumulating in systemic inflammation and ultimately multi-system organ failure. Thus, the cytokine storm plays a major role in the immunopathology of SARS-CoV-2 and is likely to be the main cause of the life-threatening respiratory disorders seen in patients with severe COVID-19.

**Elevated IL-6 and GM-CSF levels in severe COVID-19 patients**

It has been suggested that SARS-CoV-2-induced hyperactivation of proinflammatory cytokines is achieved through the NF-κB and IL-6-JAK-STAT3 signaling pathways. Studies of SARS and Middle East Respiratory Syndrome (MERS) coronaviruses that are closely related to SARS-CoV-2 have firmly established the role of
the NF-κB pathway in human coronavirus infections. Evidence that viral proteins can activate NF-κB came from studies showing that the envelop (E) protein of SARS-CoV acts as an ion channel in the virus, and is critical to viral induction of increased NF-κB activity that leads to the overproduction of inflammatory cytokines in the infected host cells. A recently reported mapping of SARS-CoV-2 and host protein–protein interactions showed that the SARS-CoV-2 E protein, which shares 96.1% sequence identity with the SARS-CoV E protein, binds BET proteins BRD2/4 in human host cells. BRD2/4 are well known to facilitate NF-κB activity in the transcriptional activation of proinflammatory cytokines.

The JAK–STAT signaling pathway plays a major role in intracellular signaling induced by IFN in hematopoietic and immune cells. It transduces extracellular signals that are transmitted by a large number of cytokines, lymphokines and growth factors. IL-6 is one of major activators of JAK–STAT signaling and has been shown to be increased substantially in COVID-19 patients, strongly implying its involvement in acute inflammation and cytokine storm. The elevated levels of IL-6 stimulate various cell types that express the membrane-bound IL-6 receptor and the glycoprotein (gp130) receptor, as well as a soluble form of the IL-6 receptor that interacts with gp130, leading to constitutive activation of JAK–STAT signaling (Fig. 2). Notably, the ability of STAT3 to promote IL6 gene expression results in an autocrine feed-forward loop, which amplifies cytokine expression. Although the mechanistic details await further study, these studies suggest that the activation of host NF-κB and IL-6–JAK–STAT signaling pathways by SARS-CoV-2 viral proteins is probably a crucial determinant of virulence, acting to promote the overexpression of proinflammatory cytokines, viral replication and pathogenicity.

IL-6 blockade has emerged as a potentially promising approach to control SARS-CoV-2-associated cytokine release syndrome (CRS) (i.e. cytokine storm). Tocilizumab is an FDA approved monoclonal antibody against IL-6 that is used for the treatment of rheumatoid arthritis (RA) and CRS accompanying CAR-T therapy for cancer, a syndrome akin to the hyperinflammatory phase of COVID-19. COVID-19 patients with severe and critical COVID-19 showed decreased counts of white blood cell and lymphocytes after receiving a 5-day treatment of tocilizumab. Accordingly, tocilizumab was approved in China for patients affected by severe SARS-CoV-2 pulmonary complications. Sarilumab, another IL-6 receptor antagonist that has been approved for the treatment of RA in patients with COVID-19, was shown to block IL-6 and to exert positive effects in COVID-19 patients with severe disease and high IL-6 levels. At present, the clinical trial involving Sarilumab for the treatment of severe COVID-19 is ongoing in the USA.

GM-CSF is a cytokine that is critical for healthy pulmonary function and is necessary for the maturation and maintenance of alveolar macrophages. Higher levels of GM-CSF were observed in the early phase of COVID-19 (1–3 days), with a progressive

**FIGURE 2**
SARS-CoV-2 induction of NF-κB and IL-6–JAK–STAT3 signaling leading to over-production of pro-inflammatory cytokines in cytokine storm including IL-6 and GM-CSF. Targeted chemical intervention against JAKs is indicated by numbered diamond. Adapted with modifications from Lim et al. BRD2/4, Bromodomain-containing protein 2/4; GM-CSF, granulocyte/macrophage colony stimulating factor; IL6, Interleukin 6; JAK, Janus kinase; STAT3, Signal transducer and activator of transcription 3; TGF-β, Transforming growth factor β; VEGF, Vascular endothelial growth factor.
decrease the late stage (day 14) of the disease. GM-CSF may contribute to ARDS indirectly by suppressing neutrophil apoptosis, as activated neutrophils can cause microvascular damage that results in lung injury. The inhibition of GM-CSF signaling may be beneficial in reducing hyperinflammation-related lung damage in the most severe cases of COVID-19. This blockade can be achieved by antagonizing the GM-CSF receptor or circulating GM-CSF. A recombinant human GM-CSF (Sargramostim) shows promising effects in improving oxygen levels in the blood of COVID patients. COVID-19 patients with hypoxic respiratory failure (saturations below 93%) are enrolled for Sargramostim treatment as a nebulized inhalation, which is administered alongside standard care for treatment. For patients with more severe COVID-19 who require mechanical ventilatory support, intravenous administration of Sargramostim will be used in the clinical study (NCT04326920). In addition, Mavrilimumab, a monoclonal antibody that binds GM-CSF receptor α, results in an improvement in oxygenation and shorter hospitalization. The anti-GM-CSF monoclonal antibodies TJ003234 and Gimsilumab will be tested in clinical trials in COVID-19 patients, whereas Lenzilumab has received FDA approval for compassionate use. Collectively, these studies support the notion that targeting IL-6 or GM-CSF and their receptors is an attractive strategy that warrants investigation as part of the current search for effective COVID-19 therapeutics.

**JAK inhibitors against human diseases**

In addition to antibodies against IL-6 and GM-CSF, FDA-approved small-molecule drugs that inhibit IL-6-JAK-STAT signaling (Fig. 3) represent a valuable clinical option for the treatment of COVID-19. JAK inhibition can affect both inflammation and cellular viral entry in COVID-19. JAK pathways are critically important for immune and hematopoietic cells, affecting processes including growth, survival, development and differentiation. Each of the JAK kinases has specificity for a different set of cytokine receptors, and thus is functionally linked to specific cytokines that bind these receptors.

Targeting of the cytokine signaling pathway with JAK inhibitors is an exciting opportunity for the treatment of immunologic and hematopoietic diseases. At present, a number of JAK inhibitors have been approved as therapeutics or are being tested in clinical trials (Table 1 and Supplementary Table 1). This section provides an overview of the clinical developments relating to the use of JAK1–3 inhibitors for the treatment of cancers and autoimmune dysfunctions.

Baricitinib (also known as Olumiant, LY3009104 and INCB028050) (Fig. 4) is a first-generation JAK inhibitor that is active against JAK1 and JAK2. It is used for the treatment of RA and other inflammatory disorders, such as plaque psoriasis and chronic atypical neutrophilic dermatosis with lipodystrophy and promoted temperatures. Tofacitinib is another first-generation highly potent JAK inhibitor, developed by Pfizer for the treatment of autoimmune diseases. It inhibits JAK1 and JAK3, and to a lesser extent, JAK2 and TYK2. In cells, Tofacitinib preferentially inhibits signaling by cytokine receptors associated with JAK3 and/or JAK1 with selectivity over receptors paired with JAK2. Peficitinib is a JAK inhibitor that is approved in Japan for the treatment of RA. This drug inhibits JAK1, JAK2, JAK3 and Tyk2 enzyme activity with IC₅₀ values of 3.9, 5.0, 0.71 and 4.8 nM, respectively. Peficitinib also inhibits IL-2-induced proliferation of human T cells (IC₅₀ = 18 nM) and was 14-fold more potent against JAK3 or JAK1 than against JAK2 in the suppression of erythropoietin-induced proliferation of human leukemia. Ruxolitinib (Fig. 4) is the first FDA-approved JAK inhibitor for the treatment of myelofibrosis, post-polycythemia vera myelofibrosis, post-essential thrombocythemia myelofibrosis, and acute graft-versus-host disease (GvHD). It has shown promising effects in autoimmune diseases such as RA, psoriasis, alopecia areata, dermatomyositis and lupus erythematosus. Fedratinib (Fig. 3) is an orally administered JAK inhibitor developed by Celgene for the treatment of intermediate-2 or high-risk primary or secondary myelofibrosis, and was second drug to be approved for the treatment of myelofibrosis after Ruxolitinib. Fedratinib, a selective JAK2 inhibitor, disrupts JAK-STAT signaling, which is overactive in patients with myelofibrosis due to JAK2V617F, CALR, or MPL mutations.

Upadacitinib or ABT494 (Fig. 4) selectively inhibits JAK1, and is approved by the US FDA for the treatment of moderate-to-severe active RA in patients who have an inadequate response to or intolerance of methotrexate. Decernotinib is a newer JAK inhibitor that has ~ five-fold selectivity toward JAK3 over JAK1, JAK2, and Tyk2 for RA. Nevertheless, the observed adverse effect of neutropenia raises the possibility that this drug inhibits other JAKs besides JAK3. Oclacitinib (PF03394197) was licensed in the EU and the US for the control of pruritus related to canine atopic dermatitis (AD) and allergic dermatitis. It selectively inhibits JAK1 in signaling pathways that induce many pro-inflammatory cytokines and has minimal effects against JAK2, which is involved in normal haematopoiesis.

Filgotinib (GLPG0634) (Fig. 4) is a reversible JAK1 preferential inhibitor, with 30- and 80-fold selectivity over JAK2 and JAK3, respectively, as determined in cellular and whole blood assays. In September 2020, Filgotinib received its first approvals in the EU and Japan for the treatment of moderate-to-severe RA in adults. Filgotinib is currently under investigation for the treatment of RA, ulcerative colitis (UC), psoriatic arthritis (PsA) and Crohn’s disease. In addition, numerous new small molecules are in the clinical and preclinical stages of development for the treatment of RA and myelofibrosis. For example, Cedulatinib (PRT062070), Itacitinib (INCB39110), AT9283, PF06700841, PF04965842, and PF06651600 are potent molecules that are at different stages of evaluation in clinical trials. In particular, Cedulatinib is multi-target tyrosine kinase inhibitor with IC₅₀ of 12, 6, 8, 0.5, 32 nM for JAK1, JAK2, JAK3, TYK2 and SYK, respectively, whereas PF06651600, Deckeritinib, Itacitinib and PF04965842 selectively inhibit JAK1 over other members of the JAK family (Fig. 4).

**Clinical investigation of JAK inhibitors in COVID-19 patients**

JAK inhibitors including Baricitinib, Ruxolitinib, Tofacitinib, Peficitinib, and Fedratinib are under clinical investigation for the treatment of COVID-19 patients who are a risk of cytokine storm (Table 2). These JAK-inhibitors, most notably Baricitinib, show promising effects in early-stage
Chemical structures of JAK2 inhibitors that are either approved by the US FDA or being evaluated in human clinical trials.
COVID-19 patients, decreasing the use of invasive mechanical ventilation and increasing survival.64 Specifically, Baricitinib treatment attenuates cytokine storm by reducing the expression levels of IL-2, IL-6, IL-10, IFN-g, and GM-CSF, resulting in rapid decline in SARS-CoV-2 viral load and improved lymphocyte counts in severely ill elderly patients with COVID-19.65–66 Baricitinib inhibits AP-2-associated protein kinase 1, which is required for SARS-CoV-2 cellular entry and infectivity.66 Baricitinib exerts rapid inhibition of host numb-associated kinases and reduces viral infectivity in human primary liver spheroids. Furthermore, Baricitinib also prevents type-1 IFN-mediated increase of ACE2 expression, and significantly reduces Tyr705-phosphorylated STAT3 (pSTAT3) level in T lymphocytes, NK cells, monocytes, and neutrophils, regularizing the immune response in COVID-19 patients.67–68 Baricitinib is generally well tolerated and produces a reduction in inflammation and improved outcomes. However, as a potent immunosuppressant, Baricitinib can lead to an additive risk of infection in severely ill patients. Baricitinib combination with Remdesivir is better than Baricitinib alone in accelerating recovery time and in improving the clinical status of COVID-19 patients on high-flow oxygen or noninvasive ventilation,69 and has fewer adverse events.

Ruxolitinib has robust activity in inhibiting JAK–STAT signaling and significantly suppresses the elevation of IL-6 and TNF-α levels in COVID-19 patients. When compared to a placebo (100 mg vitamin C, twice a day), Ruxolitinib treatment (5 mg, twice a day, a treatment dose for autoimmune or inflammatory conditions) resulted in markedly improved chest computed tomography and faster recovery from lymphopenia.70 A low dose of Ruxolitinib plus steroid reduced mortality and resulted in a 75% recovery rate in COVID-19 patients enrolled in the MAP program.71 The observation of a faster decline in CRP levels and disappearance of fever in treated patients suggests that steroids may play a synergistic role with Ruxolitinib in dampening the immune over-reactivity. Although Ruxolitinib is safe in COVID-19 patients with severe systemic hyper-inflammation, it failed to reduce inflammation significantly in those COVID-19 patients who died or who experienced respiratory failure or admission to the intensive care unit in the Phase III trial.

Tofacitinib, another JAK inhibitor that suppresses inflammatory signaling that is important for the pathological progression of severe lung disease and ARDS, has shown promising results either alone or in combination with hydroxychloroquine in a clinical study of COVID-19 patients.72 Pacritinib is also being investigated in hospitalized patients with severe COVID-19 with or without cancer (NCT04404361).73

### Potential of JAK2 inhibitors to block IL-6 receptor signaling and prevent SARS-CoV-2

One concern in using pan-JAK inhibitors for COVID-19 is that such inhibitors may interfere with antibacterial and antiviral responses that are mediated by type I and type II interferons.72–73 Type I interferons have important antiviral activity through their ability to inhibit viral replication in infected cells. They protect uninfected cells from infection and stimulate antiviral immunity by CD8+ lymphocytes and NK cells. By contrast, type II interferons are produced primarily by T cells and NK cells and help to fight against certain bacteria and to inhibit viral replication. Notably, because JAK2 is not involved in cell signaling that regulates type I interferons, and is reportedly not absolutely required for signaling of type II and type III interferons in host immunity due to functional redundancy with JAK1,74–76 JAK2 selective inhibitors may be prefered over other JAK inhibitors for blocking signaling by cytokines such as IL-6 and GM-CSF, leading to the suppression of COVID-19-associated CRS.

The development of JAK inhibitors for the treatment of COVID-19-associated CRS is an active area of investigation, with

| Compounds | Sponsor | Indication | Phase/Status/Start date | NCT Identifier |
|-----------|---------|------------|-------------------------|---------------|
| Fedratinib (Inrebic) | Sanofi | Myelofibrosis (MF), Hepatic impairment | FDA Approved/August 2019 | NCT03983161 |
| Lestaurtinib (CEP701) | Cephalon | Leukemia, MF Neuroblastoma, Acute myeloid leukemia (AML) | 1/Completed/August 2014 | NCT00084422 |
| Pacritinib (SB1518) | AbbVie | Primary myelofibrosis (PMF)/post-polycythemia vera MF, post-essential thrombocythemia MF | 3/Recruiting/May 2017 | NCT03165734 |
| Gandotinib (LY2784544) | Eli Lilly | Myeloproliferative disorders, essential thrombocythemia, polycythemia vera, PMF | 2/Terminated/August 2015 | NCT02532010 |
| Illigatinib (NS-018) | NS Pharma, Inc. | PMF, post-polycythemia vera MF, post-essential thrombocythemia MF | 1 & 2/Active, not recruiting/August 2011 | NCT01423851 |
| AZD1480 | AstraZeneca | PMF, post-polycythemia vera, essential thrombocythemia MF | 1/Completed/April 2017 | NCT00910728 |
| BMS-911543 | Bristol-Myers Squibb | Cancer | 1 & 2/Terminated/November 2010 | NCT01236352 |
| XL019 | Exelixis | Myeloproliferative disorders, MF, polycythemia vera, essential thrombocythemia | 1/Terminated/August 2007 | NCT00522574 |
multiple ongoing clinical trials. Recent studies have shown that the IL-6/GM-CSF-JAK-STAT axis is closely associated with the development of severe COVID-19 (Fig. 3). Antibodies that target IL-6 or GM-CSF normally target only one cytokine, whereas JAK inhibitors can simultaneously target the actions of multiple cytokines, including IL-2, IL-6/GM-CSF IL-4, and IFN-γ. The hypothetical benefits of JAK2 inhibition in the management of COVID-19-associated CRS are being evaluated using the FDA-approved JAK2 inhibitors. These benefits may also be provided by the improved JAK2 inhibitors that are currently being evaluated in clinical trials for other disease indications, which may be repurposed for COVID-19 in the future.

Fedratinib (1, TG101348) (Fig. 3) is a FDA-approved JAK2 inhibitor that exhibits nanomolar activity in the treatment of myelofibrosis (MF). Fedratinib has also been reported to prevent the deteriorating outcomes that occur with Th17-associated cytokine storm in COVID-19 and other severe viral infections. Some JAK2 inhibitors are currently being studied clinically for the treatment of various human diseases. For example, CEP701 (2, Lestaurtinib) (Fig. 2) is a potent JAK2 inhibitor, originally developed by Cephalon, that is being assessed in trials in multiple phases for acute myeloid leukemia (Phase 2), MF (Phases 1/2) and psoriasis (Phase 2).

Pacritinib (3, SB1518) (Fig. 3) is a JAK2/FLT3 inhibitor that has a very potent JAK2 inhibitory activity without myelosuppressive effects. In Phase 2 clinical trials, it has been shown to improve the condition of MF patients and to decrease spleen size and possibly GvHD. Gandhiubin (4, LY2784554) (Fig. 3), another potent JAK2 inhibitor, is also in Phase 2 clinical trials, in this case for myeloproliferative neoplasms including polycythemia vera, essential thrombocytopenia, MF and hematologic disorders.

Ilginatinib (5, NS018) (Fig. 3), a JAK2 inhibitor, is in Phase 1/2 clinical trials for MF. The JAK2 inhibitors AZD1480 (6), BMS911543 (7), and XL019 (8) are in advanced clinical studies for inflammatory disorders such as MF, RA, psoriatic arthritis, and ulcerative colitis. Heterocyclic compounds TG101209 (9), CEP33779 (10), 11 (4-amino-2-(4-(N-(tert-butyl)sulfamoyl)phenyl)-N-(2-

| FDA Approved |
|-------------|
| 1. Upadacitinib (ABT-494) |
| JAK1, IC50 = 8 nM |
| JAK2, IC50 = 592 nM |
| JAK3, IC50 = 464 nM |
| 2. Ruxolitinib (Jakafi-INCB018424) |
| JAK1, IC50 = 3.3 nM |
| JAK2, IC50 = 2.8 nM |
| JAK3, IC50 = 429 nM |
| 3. Baricitinib (Olumiant, LY3009104, INCBO28050) |
| JAK1, IC50 = 11 nM |
| JAK2, IC50 = 88 nM |
| JAK3, IC50 = 413 nM |
| 4. Tofacitinib |
| JAK1, IC50 = 1.5 nM |
| JAK2, IC50 = 6 nM |
| JAK3, IC50 = 8 nM |
| 5. Peficitinib (ASP0155K) |
| JAK1, IC50 = 3.9 nM |
| JAK2, IC50 = 5.7 nM |
| JAK3, IC50 = 112 nM |
| 6. Decemotinib (VX-959) |
| JAK1, IC50 = 2.5 nM |
| JAK2, IC50 = 13 nM |
| JAK3, IC50 = 11 nM |

| Clinical trails |
|----------------|
| 7. Filgotinib (GLP0634) |
| JAK1, IC50 = 10 nM |
| JAK2, IC50 = 28 nM |
| JAK3, IC50 = 810 nM |
| 8. Momelotinib (CYT387) |
| JAK1, IC50 = 11 nM |
| JAK2, IC50 = 1.5 nM |
| JAK3, IC50 = 155 nM |
| 9. Cerdulatinib (PRT602070) |
| JAK1, IC50 = 12 nM |
| JAK2, IC50 = 6 nM |
| JAK3, IC50 = 8 nM |
| 10. AT283 |
| JAK1, IC50 = 1.2 nM |
| JAK2, IC50 = 1.1 nM |
| JAK3, IC50 = N/T |
| 11. PF-06700841 |
| JAK1, IC50 = 17 nM |
| JAK2, IC50 = 77 nM |
| JAK3, IC50 = 8.500 nM |
| 12. PF-04965842 |
| JAK1, IC50 = 29 nM |
| JAK2, IC50 = 10,000 nM |
| JAK3, IC50 = 10,000 nM |
| 13. PF-06051600 |
| JAK1, IC50 = 2 nM |
| JAK2, IC50 = 10,000 nM |
| JAK3, IC50 = 10,000 nM |
| 14. Itacitinib (INCB39110) |
| JAK1, IC50 = 3.9 nM |
| JAK2, IC50 = 77 nM |
| JAK3, IC50 = 112 nM |
| 15. Solcitinib (GSK2586184) |
| JAK1, IC50 = 8 nM |
| JAK2, IC50 = 88 nM |
| JAK3, IC50 = 440 nM |
morphinoethyl) thiencarboxamide),\(^8\)\(^9\)\(^{12}\) (R)-7-(2-amino-pyrimidin-5-yl)-1-[(1-cyclo-propyl-2,2,2-trifluoroethyl) amino]-5H-pyrido[3,2-d]pyrimidine, \(^9\)\(^{13}\) (S)-N-(1-(5-fluoro-pyrimidin-2-yl) ethyl)-4-((1-methyl-1H-imidazol-4-yl)methyl)-7H-pyrrolo[2,3-b]pyridin-2-amine), \(^9\)\(^{14}\) and \(^9\)\(^{15}\) (4-(2,6-difluoro-4-(3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)quinolin-5-yl)benzyl)morpholine)\(^9\)\(^2\) (Fig. 3) exhibit significant inhibition of JAK2 in pre-clinical studies. Recently, it has been found that pyrimidine derivatives \(^9\)\(^{15}\)\(^{16}\)\(^{17}\)\(^{18}\) have 5–7-fold selectivity for JAK2 over JAK1 and JAK3.\(^9\)\(^3\) In addition, several 2-amino-pyridine scaffold compounds have also been reported as promising new JAK2 inhibitors; for example, Crizotinib \(^9\)\(^4\) and its analogs \(^9\)\(^5\)\(^{20}\)–\(^22\) exhibit nanomolar inhibitory activity and high selectivity for JAK2, and display remarkable anticancer proliferation activity.\(^9\)\(^4\)–\(^9\)\(^5\)

Given that JAK2 inhibitors probably do not interfere with the type I interferon response in immunity, but inhibit cytokines including IL-6 and GM-CSF in COVID-19-associated CRS, JAK2 inhibition is likely to offer an attractive therapeutic option for blocking cytokine storm in COVID-19.

### TABLE 2

Ongoing clinical studies of JAK inhibitors for COVID-19.

| Compounds | Organization | Combination | Phase/Status/Start date | NCT identifier |
|-----------|--------------|-------------|-------------------------|----------------|
| Ruxolitinib | Novartis | – | 3/Completed/November 2020 | NCT04362137 |
| Vanderson Geraldo Rocha | – | – | 2 & 3/Terminated/April 2021 | NCT04477993 |
| Incyte | – | – | 3/Terminated/March 2021 | NCT04577620 |
| Incyte | – | – | Temporarily not available/May 2021 | NCT04355793 |
| University of Colorado | – | – | Not yet recruiting/April 2020 | NCT04361903 |
| Azienda USI Toscana Nord Ost | – | – | Phase 2/Not yet recruiting/June 2020 | NCT04414009 |
| Marcelo lastreiber | – | – | – | – |
| Fundación de investigación HM | Simvastatin | 2/Recruiting/April 2020 | NCT04384695 |
| Washington University School of Medicine | – | – | 2/Withdrawn/2020 | NCT04354714 |
| University of Jena | – | – | 2/Recruiting/January 2021 | NCT04338958 |
| Grupo Cooperativo de Hemopatias | – | – | 1 & 2/Recruiting/February 2021 | NCT04334044 |
| Malignas | – | – | – | – |
| Prisma Health-Upstate | – | – | 2/Completed/March 2021 | NCT04374149 |
| Philips University Marburg Medical Center | – | – | 2/Active not recruited/December 2020 | NCT04359290 |
| Assistance Publique Hopitaux De Marseille | – | – | 3/Not yet recruited/ June 2020 | NCT04420456 |
| Lomonosov Moscow State University | Colchicine and Secukinumab | 2/Recruiting/May 2020 | NCT04403243 |
| Novartis Pharmaceuticals | – | – | No longer available/January 2021 | NCT04337359 |
| Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer | Anakinra | 2/Terminated/December 2020 | NCT04366232 |
| University Health Network, Toronto | – | – | – | – |
| Baricitinib | Baricitinib NIAID | – | 3/Completed/December 2020 | NCT04287070 |
| Cambridge University Hospitals NHS Foundation Trust | Remdesivir | 4/Recruiting/May 2020 | NCT04390464 |
| – | – | – | – | – |
| Fabrizio Cantini | – | – | 2 & 3/Completed | NCT04358614 |
| Hospital of Prato | – | – | 2 & 3/Not yet recruiting | NCT04320277 |
| University of Colorado | – | – | 2 & 3/Withdrawn/ March 2021 | NCT04340232 |
| University of Southern California | Hydroxychloroquine | 2/Recruiting/June 2020 | NCT04373044 |
| Eli Lilly and Company | – | – | 3/Active, not recruiting/May 2021 | NCT04421027 |
| M Abdur Rahim Medical College & Hospital | Remdesivir and Tolcizumab | 3/Recruiting/January 2021 | NCT04369306 |
| Azienda Ospedaliero Fabrizio Cantini | – | – | 2/Not yet recruiting/May 2020 | NCT04393051 |
| IRCCS Policlinico S. Matteo | – | – | 2/Not yet recruiting/May 2020 | NCT04399978 |
| ASST Fatebenefratelli Sacco | Remdesivir and Dexamethasone | 3/Recruiting/April 2020 | NCT04832880 |
| Hospital Universitario de Fuenlabrada | Imapitinib | 2/Recruiting/February 2021 | NCT04346147 |
| ComplejoHospitalario Universitario de Albacete | – | – | Recruiting/April 2020 | NCT04362943 |
| Lisa Barrett | – | – | 2/Recruiting/June 2020 | NCT04321993 |
| Tofacitinib | Yale University | – | 2/Recruiting/February 2021 | NCT04415151 |
| Pfizer | – | – | 2/Withdrawn/February 2021 | NCT04412252 |
| Hospital Israelita Albert Einstein | – | – | 2/Active, not recruiting/February 2021 | NCT04469114 |
| I.M. Sechenov First Moscow State Medical University | – | – | 2/Completed/March 2021 | NCT04750317 |
| University | – | – | – | – |
| Università Politecnica delle Marche | Hydroxychloroquine | 2/Not yet recruiting/May 2020 | NCT04390601 |
| Università Politecnica delle Marche | – | – | 2/Not yet recruiting/April 2020 | NCT04332042 |
| Pacritinib | CTI BioPharma | – | 3/Not yet recruiting/April 2020 | NCT04404361 |

Notes: ‘–’, no combination.
Conclusions
Recent clinical observations have led to the rapid recognition of the major role played by cytokine storm in the deterioration of SARS-CoV-2 patients from pneumonia through ARDS, to systemic inflammation and ultimately multi-system organ failure. Pharmacological inhibition of the JAK-STAT signaling pathway is an attractive therapeutic option for the management of COVID-19, which involves many cytokines including IL-6 and GM-CSF. Drugs such as Tocilizumab and Sarilumab have been shown to target IL-6, and consequently improve the respiratory and laboratory parameters of patients with severe and critical COVID-19. Small molecule JAK inhibitors have added advantages as therapeutics as they can target the actions of multiple cytokines, including IL-6 and GM-CSF, simultaneously. JAK inhibitors such as Baricitinib have been shown to minimize the cytokine storm effectively via inhibition of the JAK-STAT signaling pathway and may reduce both viral replication and aberrant host inflammatory response. Given that JAK2 inhibitors have been shown not to interfere with cell signaling by type I interferons, which is essential for the anti-viral immunity of the host cells.96 Fedatrinib, an FDA-approved JAK2 inhibitor, could be used to prevent COVID-19-associated cytokine storm with minimal effects on the host immune system. Several potent JAK2 inhibitors that are currently being evaluated in human clinical trials, as well as drugs that have already been FDA approved, have been shown to be moderately effective in controlling host antiviral and anti-bacterial immunity responses. Lestaurtinib (CE701), Pacritinib, AZD1480, BMS-911543, Filgotinib (NS108), TG101209 and Gandotinib are among the JAK2-selective inhibitors that have been studied in clinical and preclinical trials for MF, RA and other inflammatory disorders. These JAK2 inhibitors can also be tested for the treatment of COVID-19, either as monotherapies or in combination with IL-6 or IL-6R antagonists. Therefore, these JAK2 inhibitors represent an attractive therapeutic option that we hope will be developed into much-needed therapeutics to treat and prevent the devastating effects of COVID-19.

Acknowledgements
We thank members of the Zhou group for helpful discussions. This work was supported in part by research grants from the National Institutes of Health (RO1AI124465 to M.-M.Z.).

References
1. WHO. Coronavirus disease (COVID-19). Situation Report – 199. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200806-covid-19-sitrep-199.pdf?sfvrsn=6bd9262d_2. Published August 6, 2020 (accessed May 28, 2021).
2. C. Wang, W.F. Horby, F.G. Hayden, G.F. Gao. Coronavirus outbreak of global health concern, Lancet 395 (2020) 470–473, https://doi.org/10.1016/S0140-6736(20)30185-9.
3. D. Wang, B. Hu, C. Hu, F. Zhu, X. Liu, J. Zhang, et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA 323 (2020) 1061–1069, https://doi.org/10.1001/jama.2020.1585.
4. C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395 (2020) 497–506, https://doi.org/10.1016/S0140-6736(20)30183-5.
5. N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, et al., A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med 382 (2020) 727–733, https://doi.org/10.1056/NEJMoa2001017.
6. P. Yi, N.P. Lagnitton, S. Ye, E. Li, R.H. Xu, COVID-19: what has been learned and to be learned about the novel coronavirus disease, Int J Biol Sci 16 (2020) 1753–1766, https://doi.org/10.7150/ijb.45134.
7. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Gernher A, Grass M, et al., The origin, transmission and clinical therapies on SARS-CoV-2 and COVID-19: the status of the science at the 24 February 2020, Curr Opin Virol 36 (2020) 103–109, https://doi.org/10.1016/j.coviro.2020.02.009.
8. A.C. Walls, M.A. Tortorici, B.J. Bosch, B. Frenz, P.J.M. Rottier, F. DiMaio, et al., Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer, Nature 531 (2016) 114–117, https://doi.org/10.1038/nature17666.
9. R.N. Kirchdoerfer, C.A. Cottrell, N. Wang, J. Pallesen, J. Wu, D. himself et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell 181 (2020) 271–280, https://doi.org/10.1016/j.cell.2020.02.052.
10. F.V. Li, Structure, function, and evolution of coronavirus spike proteins, Annu Rev Virol 7 (2020) 362, https://doi.org/10.1146/annurev-virology-110615-042030.
11. Y. Shi, Y. Wang, C. Shao, J. Huang, J. Gan, X. Huang, et al., COVID-19 infection: the perspectives on immune responses, Cell Death Differ 27 (2020) 1451–1454, https://doi.org/10.1038/s41418-020-0530-3.
12. E. Gallard, F.X. Leschtre, Y. Yazdanpanah, F. Mentre, N. Peiffer-Smadja, Type 1 interferons as a potential treatment against COVID-19, Antiviral Res 178 (2020), https://doi.org/10.1016/j.antiviral.2020.104791.
13. M. Messad, J.C. Martin, Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages, Nat Rev Immunol 20 (2020) 355–362, https://doi.org/10.1038/s41577-020-0331-4.
14. L.F. García, Immune response, inflammation, and the clinical spectrum of COVID-19, Front Immunol 11 (2020) 1441, https://doi.org/10.3389/fimmu.2020.01441.
15. T.M. Gallagher, M.J. Buchmeier, Coronavirus spike proteins in viral entry and pathogenesis, Virology 279 (2001) 371–374, https://doi.org/10.1006/viro.2000.0757.
16. R.N. Kirkdowner, C.A. Cottrell, N. Wang, J. Pallesen, H.M. Yassine, H.L. Turner, et al., Pre-fusion structure of a human coronavirus spike protein, Nature 531 (2016) 118–121, https://doi.org/10.1038/nature17200.
17. Y.R. Guo, Q.D. Cao, Z.S. Hong, Y.Y. Tan, S.D. Chen, H.J. Jin, et al., The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak — an update on the status, Mil Med Res 7 (2020) 11, https://doi.org/10.1186/s40779-020-00240-0.
18. P. Mehta, D.F. McAuley, M. Brown, E. Sanchez, R.S. Tattersall, J.J. Manson, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet 395 (2020) 1033–1038, https://doi.org/10.1016/S0140-6736(20)30628-0.
19. E.J. Giaremiadi-Bourboulis, M.G. Netka, N. Rovina, K. Akinsoglou, A. Antoniadou, N. Antonakos, et al., Complex immune dysregulation in COVID-19 patients with severe respiratory failure, Cell Host Microbe 27 (2020) 992–1000, https://doi.org/10.1016/j.chom.2020.04.009.
20. C. Melenotte, A. Silvin, A.G. Goubet, I. Lahmar, A. Dubuisson, A. Zumla, et al., Immune responses during COVID-19 infection, Onc Immunology 9 (2020) 1807836, https://doi.org/10.1080/20423260.2020.1807836.
21. E.J. Giaremiadi-Bourboulis, M.G. Netka, N. Rovina, K. Akinsoglou, A. Antoniadou, N. Antonakos, et al., Complex immune dysregulation in COVID-19 patients with severe respiratory failure, Cell Host Microbe 27 (2020) 992–1000, https://doi.org/10.1016/j.chom.2020.04.009.
30. S.F. Dosch, S.D. Mahajan, A.R. Collins, SARS coronavirus spike protein-induced immune response occurs via activation of the NF-κappaB pathway in human monocyte macrophages in vitro, J Virol Res 14 (2007) 19–27, https://doi.org/10.1016/j.jvir.2009.01.005.

31. S.Y. Fung, K.S. Yuen, Z.W. Ye, C.P. Chan, D.Y. Jin, A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses, Emerg Microbes Infect 9 (2020) 558–570, https://doi.org/10.1080/22221751.2020.1736644.

32. Y.X. Lim, Y.L. Ng, J.P. Tam, D.X. Liu, Human Coronaviruses: a review of virus-host interactions, Dis Mon 66 (2020) 26, https://doi.org/10.1038/s41375-020-00302-6.

33. M.L. DeDiego, J.L. Nieto-Torres, J.A. Regla-Nava, J.M. Jimenez-Guardaño, R. Fernandez-Delgado, C. Fett, et al., Inhibition of NF-κB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival, J Virol 88 (2014) 913–924, https://doi.org/10.1128/JVI.02576-13.

34. D. Schoeman, B.C. Fielding, Coronavirus envelope protein: current knowledge, Virol J 16 (2019) 69, https://doi.org/10.1186/s12985-019-1188-2.

35. M.L. DeDiego, J.L. Nieto-Torres, J.M. Jimenez-Guardaño, J.A. Regla-Nava, C. Castaño-Rodrigo, R. Fernandez-Delgado, et al., Coronavirus virulence genes with main focus on SARS-CoV envelope gene, Virus Res 194 (2014) 124–137, https://doi.org/10.1016/j.virusres.2014.07.024.

36. Gordon DE, Jang GM, Bouhadou M, Xu J, Obernier K, O’Meara MJ, et al. SARS-CoV-2-human protein–protein interaction map reveals drug targets and potential drug-repurposing. bioRxiv 2020; 2020.03.22.002386. doi: 10.1101/2020.03.22.002386.

37. G. Zhang, R. Liu, Y. Zhong, A.N. Piotnowik, W. Zhang, L. Zeng, et al., Down-regulation of NF-κB transcriptional activity in HRV-associated kidney disease by BRD4 inhibition, J Biol Chem 287 (2012) 28840–28851, https://doi.org/10.1074/jbc.M112.395505.

38. M. Gadina, M.T. Le, D.M. Schwartz, O. Silvennoinen, S. Kang, T. Tanaka, M. Narazaki, T. Kishimoto, et al., Targeting GM-CSF in COVID-19 pneumonia: rationale and strategies, Front Immunol 11 (2020) 1625, https://doi.org/10.3389/fimmu.2020.01625.

39. C. Bosteels, B. Baes, K. Van Damme, E. De Leeuw, J. Declercq, A. Delporte, et al., Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SAPAC): a structured summary of a controlled randomized trial, Trials 21 (2020) 491, https://doi.org/10.1186/s13063-020-04511-7.

40. X. Qiang, S. Zhu, J. Li, P. Wang, K.J. Tracey, H. Wang, et al., Monoclonal antibodies capable of binding SARS-CoV-2 spike protein-recipient binding motif specifically prevent GM-CSF induction, J Leukoc Biol (2021), https://doi.org/10.1002/jlb.OC2020-268RR.

41. S. Ajayi, H. Becker, H. Reinhardt, M. Engelhard, R. Zeiser, N. von Bubnoff, R. Wäsch, Ruxolitinib, Recent Results Cancer Res 212 (2018) 119–132, https://doi.org/10.1007/978-3-319-91439-8_6.

42. J. Stebbing, G. Sánchez Nievas, M. Falcone, S. Youhanan, P. Richardson, et al., JAK inhibition reduces SARS-COV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality, Sci Adv 7 (2021) eabc4724, https://doi.org/10.1126/sciadv.abc4724.

43. Z.T. Al-Salama, L.J. Scott, Baricitinib: a review in rheumatoid arthritis, Drugs 78 (2018) 761–772, https://doi.org/10.1007/s40265-018-0908-4.

44. S. Dhillon, Tofacitinib: a review in rheumatoid arthritis, Drugs 77 (2017) 1987–2001, https://doi.org/10.1007/s40265-017-0636-6.

45. A. Markham, S.J. Keam, Peficitinib: first global approval, Drugs 79 (2019) 887–891, https://doi.org/10.1007/s40265-019-01131-y.

46. M. Ito, S. Yamazaki, K. Yamagami, M. Kuna, Y. Morita, K. Okuma, et al., A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model, J Pharmaco Invest 130 (2020) 6409–6415, https://doi.org/10.1172/JCI141772.

47. J. Stebbing, V. Krishnan, S. Bono, S. Ottaviani, G. Casalini, P.J. Richardson, et al., Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients, EMBO Mol Med 12 (2020), https://doi.org/10.15252/emmm.202012697.

48. Hoang TN, Pino M, Boddapati AK, Viox EG, Starke CE, Upadhyay AA, et al. Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. Cell 2021;184:75–75.e21. doi: 10.1016/j.cell.2021.07.027.

49. V. Bronte, S. Ugel, E. Tinazzi, A. Vella, F. Sanzti, S. Cané, et al., Baricitinib restrains the immune dysregulation in patients with severe COVID-19, J Clin Invest 130 (2020) 6409–6416, https://doi.org/10.1172/JCI141772.

50. A.C. Kae, F.T. Patterson, A.K. Mehta, K.M. Tomasheski, C.R. Wolfe, V. Ghazaryan, et al., Baricitinib plus Remdesivir for hospitalized adults with Covid-19, N Engl J Med 384 (2021) 795–807, https://doi.org/10.1056/NEJMoA2031994.

51. K.T. Chow, M. Gale Jr., Snapshot: interferon signaling, Cell 163 (2015) 1808–1808e1, https://doi.org/10.1016/j.cell.2015.12.008.
76. L.C. Platianis, Mechanisms of type-I- and type-II-interferon-mediated signalling, Nat Rev Immunol 5 (2005) 375–386, https://doi.org/10.1038/nri1604.
77. Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol 2020;146:137–46.e3. doi: 10.1016/j.jaci.2020.05.019
78. A. D’Alessio, P. Del Poggio, F. Bracchi, G. Cesana, N. Sertori, D. Di Mauro, et al., Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia, Leukemia 35 (2021) 635–638, https://doi.org/10.1038/s41375-020-01087-2.
79. M. Agrawal, E.J. Brenner, X. Zhang, I. Modesto, J. Muller, D.J. Kelvin, Human immunopathogenesis of severe acute respiratory syndrome (SARS), Virus Res 133 (2008) 13–19, https://doi.org/10.1016/j.virusres.2007.02.014.
80. B.C. Betts, J.W. Young, Less can be more when targeting Interleukin-6-mediated cytokine release syndrome in Coronavirus Disease 2019, Crit Care Explor 2 (2020), https://doi.org/10.1093/ccrcc/ejz018.
81. M.J. Cameron, J.F. Bermejo-Martin, A. Danesh, M.P. Muthukumaran, K. Paukku, O. Silvennoinen, et al., Characteristics and outcomes of iBD patients with COVID-19 on tofacitinib therapy in the SECURE-iBD registry, Inflamm Bowel Dis 27 (2021) 585–589, https://doi.org/10.1093/ibd/iaaa303.
82. R. Channappanavar, A.R. Fehr, J. Zheng, C. Wohlford-Lenane, J.E. Marvin, J.T. Prchal, et al., Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F inhibitor, in a murine model of myeloproliferative neoplasms, Leukemia Res 71 (2018) 88, https://doi.org/10.1016/j.leukres.2018.06.014.
83. S.V. Kotenko, L.S. Izotova, B.P. Pollack, G. Muthukumaran, K. Paukku, O. Silvennoinen, et al., Other kinases can substitute for Jak2 in signal transduction by interferon-gamma, J Biol Chem 271 (1996) 17174–17182, https://doi.org/10.1074/jbc.271.29.17174.
84. F.R. Spinelli, F. Conti, M. Gadina, HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19, Sci Immunol 5 (2020) eabc5367, https://doi.org/10.1126/sciimmunol.abc5367.
85. S. Atal, Z. Fatima, IL-6 inhibitors in the treatment of serious COVID-19: a promising therapy?, Pharmaceut Med 34 (2020) 223–231, https://doi.org/10.1007/s40290-020-00342-z.
86. D. Tremblay, J. Mascarenhas, Pacitnib to treat myelofibrosis patients with thrombocytopenia, Expert Rev Hematol 11 (2018) 707–714, https://doi.org/10.1080/17474086.2018.1500456.
87. D. Wu, X.O. Yang, TH17 responses in cytokine storm of COVID-19: an emerging target of JAK inhibitor Fedritabin, J Microbiol Infect Dis 5 (2020) 368–370, https://doi.org/10.1016/j.jmii.2020.03.005.
88. E.O. Hexner, C. Serdikoff, M. Jan, C.R. Swider, C. Robinson, S. Yang, et al., Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders, Blood 111 (2008) 5663–5671, https://doi.org/10.1182/blood-2007-04-083402.
89. J. Berdeja, F. Palandri, M.R. Baer, D. Quick, J.J. Kiladjian, G. Martinelli, et al., Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms, Leukemia Res 71 (2018) 82–88, https://doi.org/10.1016/j.leukres.2018.06.014.
90. Y. Nakaya, K. Shide, H. Naito, T. Niwa, T. Horio, J. Miyake, K. Shimoda, Effect of NS-018, a selective JAK2 inhibitor that suppresses JAK2/STAT5 signaling in mice, J Immunol 200 (2008) 5671, https://doi.org/10.4049/jimmunol.179.11.5671.
91. S. Verstovsek, C.S. Tam, M. Wadleigh, L. Sokol, C.C. Smith, L.A. Bui, et al., Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor, Leukemia Res 38 (2014) 316–322, https://doi.org/10.1016/j.leukres.2013.12.006.
92. A. Pardanani, J. Hood, T. Lasho, R.L. Levine, M.B. Martin, G. Noronha, et al., TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations, Leukemia 21 (2007) 1658–1668, https://doi.org/10.1038/sj.leu.2404750.
93. V. D’Souza, S. DeRosa, G. Cesana, J. Fehr, J. Prchal, et al., A highly selective, orally active inhibitor of Janus kinase 2, CEPI-701, reduces disease in two mouse models of rheumatoid arthritis, Arthritis Res Ther 13 (2011) R68, https://doi.org/10.1186/ar3329.
94. J. Lim, B. Taoka, R.D. Otte, K. Spencer, C.J. Dinsmore, Gajjela Bharath Kumar, Ming-Ming Zhou* Corresponding author.
Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA